Wali Arvin R, Park Charlie C, Brown Justin M, Mandeville Ross
Departments of 1 Neurological Surgery and.
Radiology, University of California, San Diego, California.
Neurosurg Focus. 2017 Mar;42(3):E11. doi: 10.3171/2016.12.FOCUS16469.
OBJECTIVE Peripheral nerve transfers to regain elbow flexion via the ulnar nerve (Oberlin nerve transfer) and median nerves are surgical options that benefit patients. Prior studies have assessed the comparative effectiveness of ulnar and median nerve transfers for upper trunk brachial plexus injury, yet no study has examined the cost-effectiveness of this surgery to improve quality-adjusted life years (QALYs). The authors present a cost-effectiveness model of the Oberlin nerve transfer and median nerve transfer to restore elbow flexion in the adult population with upper brachial plexus injury. METHODS Using a Markov model, the authors simulated ulnar and median nerve transfers and conservative measures in terms of neurological recovery and improvements in quality of life (QOL) for patients with upper brachial plexus injury. Transition probabilities were collected from previous studies that assessed the surgical efficacy of ulnar and median nerve transfers, complication rates associated with comparable surgical interventions, and the natural history of conservative measures. Incremental cost-effectiveness ratios (ICERs), defined as cost in dollars per QALY, were calculated. Incremental cost-effectiveness ratios less than $50,000/QALY were considered cost-effective. One-way and 2-way sensitivity analyses were used to assess parameter uncertainty. Probabilistic sampling was used to assess ranges of outcomes across 100,000 trials. RESULTS The authors' base-case model demonstrated that ulnar and median nerve transfers, with an estimated cost of $5066.19, improved effectiveness by 0.79 QALY over a lifetime compared with conservative management. Without modeling the indirect cost due to loss of income over lifetime associated with elbow function loss, surgical treatment had an ICER of $6453.41/QALY gained. Factoring in the loss of income as indirect cost, surgical treatment had an ICER of -$96,755.42/QALY gained, demonstrating an overall lifetime cost savings due to increased probability of returning to work. One-way sensitivity analysis demonstrated that the model was most sensitive to assumptions about cost of surgery, probability of good surgical outcome, and spontaneous recovery of neurological function with conservative treatment. Two-way sensitivity analysis demonstrated that surgical intervention was cost-effective with an ICER of $18,828.06/QALY even with the authors' most conservative parameters with surgical costs at $50,000 and probability of success of 50% when considering the potential income recovered through returning to work. Probabilistic sampling demonstrated that surgical intervention was cost-effective in 76% of cases at a willingness-to-pay threshold of $50,000/QALY gained. CONCLUSIONS The authors' model demonstrates that ulnar and median nerve transfers for upper brachial plexus injury improves QALY in a cost-effective manner.
目的 通过尺神经(奥伯林神经移位术)和正中神经进行周围神经移位以恢复肘关节屈曲是使患者受益的手术选择。先前的研究评估了尺神经和正中神经移位术治疗臂丛上干损伤的相对有效性,但尚无研究探讨该手术改善质量调整生命年(QALY)的成本效益。作者提出了一个成本效益模型,用于评估奥伯林神经移位术和正中神经移位术在成年臂丛上干损伤患者中恢复肘关节屈曲的情况。方法 作者使用马尔可夫模型,模拟了尺神经和正中神经移位术以及保守治疗措施对臂丛上干损伤患者神经功能恢复和生活质量(QOL)改善的情况。转移概率取自先前评估尺神经和正中神经移位术手术疗效、类似手术干预相关并发症发生率以及保守治疗自然病程的研究。计算了增量成本效益比(ICER),定义为每获得一个QALY的成本(以美元计)。ICER小于50,000美元/QALY被认为具有成本效益。采用单向和双向敏感性分析评估参数不确定性。使用概率抽样评估100,000次试验的结果范围。结果 作者的基础模型表明,尺神经和正中神经移位术估计成本为5066.19美元,与保守治疗相比,一生中有效性提高了0.79个QALY。在未对因肘关节功能丧失导致的终生收入损失的间接成本进行建模的情况下,手术治疗的ICER为每获得一个QALY 6453.41美元。将收入损失作为间接成本考虑在内,手术治疗的ICER为每获得一个QALY -96,755.42美元,这表明由于恢复工作的可能性增加,总体终生成本节省。单向敏感性分析表明,该模型对手术成本、良好手术结果概率以及保守治疗神经功能自发恢复的假设最为敏感。双向敏感性分析表明,即使采用作者最保守的参数,即手术成本为50,000美元且成功率为50%,考虑到通过恢复工作获得的潜在收入,手术干预的ICER为18,828.06美元/QALY,仍具有成本效益。概率抽样表明,在每获得一个QALY支付意愿阈值为50,000美元的情况下,手术干预在76%的病例中具有成本效益。结论 作者的模型表明,尺神经和正中神经移位术治疗臂丛上干损伤以具有成本效益的方式提高了QALY。